Trial Profile
Study of switching to tenofovir alafenamide (TAF) avoid organ toxicity associated with other anti-hepatitis B virus (HBV) medications in chronic HBV positive patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2018
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- 09 Nov 2018 New trial record
- 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018